SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
about
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylationProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaSKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedTyrosine kinase-mediated axial motility of basal cells revealed by intravital imagingStructural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainDevelopment of novel ACK1/TNK2 inhibitors using a fragment-based approachRetinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyBosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.SRC: a century of science brought to the clinic.Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibEGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Phosphoproteomics in cancerInduced protein degradation: an emerging drug discovery paradigm.When will resistance be futile?Monitoring response and resistance to treatment in chronic myeloid leukemia.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formationElevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.Cooperation between VEGF and beta3 integrin during cardiac vascular development.Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signalingSKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancerIn vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold.Tubedown regulation of retinal endothelial permeability signaling pathways.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.TSLP signaling network revealed by SILAC-based phosphoproteomicsFunctions of the Lyn tyrosine kinase in health and disease
P2860
Q24298234-21392C11-84A1-4BA2-8F8F-82CFDD80E4A9Q24607114-1F29EB25-D8D0-4A29-AD84-B0BFD5722540Q24656966-BA0967F8-86E8-4F48-A3DE-2DB1703ACAE2Q26738514-09FC6C58-E3C3-45BB-8859-036DBBE603DEQ27332421-9D1687C5-F888-4595-A3EB-6E1227B98D8DQ27678454-36E42889-9862-4A02-9D26-2BAB5A3C998DQ28257452-05D63BF2-13E6-49B7-8723-0F87EDF9C1AFQ33335166-F2976FB3-EFBF-47CC-A390-3E17AEC269AAQ33584613-294E6274-9291-40B3-AC6D-7A3ABE1EC92DQ33823065-433EA45C-4868-4594-B082-88D369D2E578Q33828409-2E6907E6-6307-4889-964C-19E309A85A4FQ34026441-EFA8C972-CB09-406E-957A-0FFA79B708DCQ34041298-EEE370D1-6E0B-499B-B28F-1F11EA449F45Q34056631-D6B80826-AE64-4BAE-B041-2CF2854AF7A8Q34210528-61D63DCC-6807-42F4-A803-8C9D276ADFD3Q34269196-C4CB305C-C746-49A5-948E-A6CAA2AC8E3CQ34297594-0659E5F9-D617-47DE-9E4F-A18AD5F07808Q34417824-117E9E76-B750-4C71-8737-08DCD9594349Q34539788-4804A02A-AED3-41F6-BEEE-1B390812E6E9Q34545841-0F6DBD58-AF54-4D1C-A645-66F54143E6FDQ34715457-A26BD2DE-F3D6-4C5C-8DC7-D7BF3B5D3FC0Q34761663-F73A9B55-4E1D-4F90-94FF-FA3F2419C3A7Q34763374-ADD849AE-A422-4BEA-B959-A7B7123D7763Q34959208-2C093BB2-8FE0-4644-A454-02A3339088DBQ35070978-579FE436-AA1D-49EE-96F2-02B3D1BF82CFQ35159468-D98C316A-8273-4C2D-A082-FB52E2839E97Q35470183-DB7F743B-C081-4B88-A2C7-CB817A4D5436Q35570442-DB34B9D3-8029-4DE3-9E88-450398C047AAQ35640320-9A0A8E35-2C4E-47C8-88ED-C6E2A0BAF78FQ35642757-8D5D7BAF-99B4-4865-BA35-92E89EC1D430Q35665700-127F7597-CE44-40C1-BCC2-EBFBC828AC45Q35803259-FA318628-FC28-4BE3-97ED-17EC078BC1E0Q35803670-C7A54A6C-78BC-4FCC-A0E8-FB408541F1E8Q35819214-B56465B0-4969-484B-A5AD-F01CC304369FQ35942258-CC348557-3D25-439B-98B8-C54672332C8EQ35973301-7E9D905F-C88D-42F5-B242-A5B99B488D80Q36140620-543D8F15-AAA4-4231-BF6A-802D46C040A9Q36169317-9C854A60-B554-473F-AE39-13F40F4042AAQ36208936-BA135B06-DA4D-443C-95AD-3AE394303D3DQ36299576-BECCE5EF-A291-4D43-B586-620045B55631
P2860
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
SKI-606, a 4-anilino-3-quinoli ...... K562 xenografts in nude mice.
@en
SKI-606, a 4-anilino-3-quinoli ...... K562 xenografts in nude mice.
@nl
type
label
SKI-606, a 4-anilino-3-quinoli ...... K562 xenografts in nude mice.
@en
SKI-606, a 4-anilino-3-quinoli ...... K562 xenografts in nude mice.
@nl
prefLabel
SKI-606, a 4-anilino-3-quinoli ...... K562 xenografts in nude mice.
@en
SKI-606, a 4-anilino-3-quinoli ...... K562 xenografts in nude mice.
@nl
P2093
P1433
P1476
SKI-606, a 4-anilino-3-quinoli ...... K562 xenografts in nude mice.
@en
P2093
Carlo Etienne
Danielle Nardin
Diane H Boschelli
Frank Boschelli
James Gibbons
Jennifer M Golas
Judy Lucas
Philip Frost
P304
P407
P577
2003-01-01T00:00:00Z